eCOA vs ePRO: what are the differences in clinical trials?

Written by
Florentin Ory
Published on
22 May 26
Updated on
19 Nov 26
ePRO and eCOA for your patients
Key takeaways
  • ePRO is one of the four assessment types eCOA covers, alongside ClinRO, ObsRO and PerfO (FDA, 2025).
  • ePRO alone covers a study only when every outcome assessment comes from the patient's own report, without interpretation.
  • A single clinician-rated, caregiver-observed or task-based endpoint puts the study in the wider eCOA scope.
  • The EMA expects an alternative to BYOD for participants unable or unwilling to use their own device (2023).
  • When a sensor or wearable produces the measurement itself, the FDA refers to its 2023 guidance on digital health technologies.

ePRO (electronic Patient-Reported Outcome) is one of the four data types collected under eCOA (electronic Clinical Outcome Assessment): the one reported directly by the patient, with no clinician or observer in between. eCOA is the umbrella framework; ePRO, eClinRO, eObsRO and ePerfO are its four data sources. Every ePRO data point is an eCOA data point, but an eCOA program can run without ever using ePRO, if the protocol only calls for clinician-reported or performance-based assessments. The role of ePRO in a trial goes beyond questionnaires: reminders, time windows, compliance tracking.

Understanding how they interact helps clinical teams and sponsors design more robust protocols, improve data collection reliability, and deliver a smoother patient experience. In an industry where data quality directly impacts trial validity, making the right methodological choice during the study design phase is critical.

While these two tools share the same objective, they are not used in the same situations and do not address the same needs. ePRO is a component of eCOA, not its equivalent. Understanding this distinction is essential for sponsors looking to optimize patient monitoring and improve result reliability.

eCOA and ePRO: what do they actually mean?

eCOA (electronic Clinical Outcome Assessment) refers to the electronic collection of Clinical Outcome Assessments, meaning evaluations used to measure a participant’s health status, symptoms, functional abilities, or quality of life.

eCOA includes four types of assessments:

  • ePRO: outcomes reported directly by the patient
  • eClinRO: outcomes reported by a clinician
  • eObsRO: outcomes reported by an observer such as a caregiver or parent
  • ePerfO: outcomes based on performance tests completed by the patient

ePRO focuses specifically on information reported directly by the patient, without interpretation from a healthcare professional. It enables real-time capture of information related to quality of life, symptoms, or patient experience throughout the study.

This makes ePRO the right tool when only the patient can report the outcome, such as pain intensity or fatigue.

What are the main differences between eCOA and ePRO?

The fundamental difference lies in the source of the data. eCOA aggregates information coming from multiple stakeholders involved in the trial, including physicians, nurses, caregivers, and patients, while ePRO relies exclusively on patient-reported information. As a result, their role within a clinical protocol differs significantly.

CriteriaeCOAePRO
DefinitionGlobal framework for electronic clinical outcome collectioneCOA subcategory focused on patient-reported data
Data sourceMultiple: clinicians, caregivers, patientsPatient only
Measurement typesPRO, ClinRO, ObsRO, PerfOSymptoms, pain, fatigue, quality of life
Who completes it?Depending on the assessment type: clinician, caregiver, or patientPatient only
Typical use caseComplex multi-stakeholder protocolsStudies focused on patient experience
Real-time collection✓ Yes✓ Yes
Regulatory complianceFDA 21 CFR Part 11; EMA guideline on computerised systems (2023)FDA 21 CFR Part 11; EMA guideline on computerised systems (2023)

In practice, how should you differentiate them?

  • eCOA is used when the protocol involves multiple assessment sources including clinical teams, caregivers, and patients.
  • ePRO is preferred when the study focuses on subjective patient experience such as pain, fatigue, well-being, or treatment adherence.
  • eCOA includes ePRO: every ePRO outcome is an eCOA outcome, but not every eCOA outcome is ePRO.

[[cta]]

BYOD vs provisioned devices: two deployment approaches

Many ePRO solutions offer a BYOD (Bring Your Own Device) approach. Participants use their own smartphone, tablet, or computer to complete questionnaires.

This approach helps:

  • reduce logistical costs
  • accelerate international deployment
  • avoid device distribution and maintenance
  • provide a familiar experience for participants

In some studies, sponsors provide dedicated devices known as provisioned devices. This approach remains useful when the protocol requires a standardized technical environment or when participants do not have compatible equipment.

BYOD is common, especially in decentralized clinical trials. Under the EMA guideline on computerised systems (2023), a participant who cannot or does not want to use their own device should not be excluded: the sponsor must offer another way to answer, such as a provisioned device.

What are the benefits for clinical research?

Adopting these electronic solutions in a clinical trial provides concrete benefits for sponsors, site teams, and patients alike.

Improved data reliability: electronic data capture reduces transcription errors and missing information commonly associated with paper-based processes.

Real-time data collection: each entry is timestamped when the patient makes it and reaches the server straight away, or at predefined times when an app stores it on the device first, so the study team can follow patients between visits.

Better patient engagement: questionnaires accessible through mobile devices or tablets simplify participation, especially for patients located far from the clinical site.

Centralized data management for sponsors: data oversight becomes easier, with improved visibility into trial progress.

Examples of applications and best practices

In an oncology trial, an ePRO platform may be used to monitor fatigue or pain experienced by the patient between site visits. These patient-reported data points, collected without intermediary interpretation, significantly enrich the clinical record.

At the same time, eClinRO, as part of the broader eCOA framework, allows investigators to document their own observations during each patient visit.

For successful implementation, several best practices should be followed:

  • Clearly define in the protocol which outcome types are expected such as PRO, ClinRO, or ObsRO before selecting a solution.
  • Train site teams on electronic interfaces to ensure consistent data collection.
  • Provide patient support from study inclusion onward to maximize adherence to ePRO questionnaires.
  • Ensure the selected solution complies with regulatory requirements including FDA 21 CFR Part 11 and the EMA guideline on computerised systems and electronic data in clinical trials (2023).

Datacapt runs ePRO in the same platform as the eCRF: patients answer on their own device or a provisioned one, reminders go out automatically, and the study team tracks completion in real time.

When is ePRO enough, and when does a study need full eCOA?

ePRO is enough when every clinical outcome assessment in the protocol comes from the patient's own report. As soon as one endpoint needs a clinician's judgment, a caregiver's observation or a standardized task, the study needs the wider eCOA scope. In its October 2025 guidance on clinical outcome assessments, the FDA states that more than one type of COA can be used in the same trial.

The table starts from the endpoints in your protocol and shows which ones ePRO covers on its own.

Endpoint in your protocolAssessment type (FDA, 2025)What it means for the system
A symptom diary or quality-of-life questionnaire the patient completes, such as EQ-5D or SF-36PROePRO covers the study on its own
A severity score the investigator rates at the visit, such as EASI in atopic dermatitisClinROeCOA: the investigator enters the rating at the site (eClinRO)
A diary kept by the parents of children too young to answer for themselvesObsROeCOA: the parent reports as an observer, not on the child's behalf (eObsRO)
A timed walking or dexterity test done at the site, such as the Timed 25-Foot WalkPerfOeCOA: the site records the result of the task (ePerfO)
Step count or sleep recorded by a wearableOutside the four COA types: the FDA refers to its December 2023 guidance on digital health technologiesOutside the four eCOA types

In a pediatric study, older children can answer an ePRO questionnaire while the parents of the youngest complete an eObsRO. The parents describe what they observe and do not answer as if they were the child, a practice the FDA discourages as proxy reporting.

Once you know which assessment types your protocol needs, our comparison of ePRO and eCOA software sets out the criteria for choosing a vendor.

[[faq]]

Sources

ePRO and eCOA for your patients
See Datacapt on your own study
Tell us who reports outcomes in your study. We show the ePRO and eCOA screens your patients and sites would use.
A 30-minute call on your protocol, your sites and the modules you need.

Frequently asked questions

Still have a question? Talk to our team.

What is the difference between eCOA and ePRO?

eCOA (electronic Clinical Outcome Assessment) is the umbrella term for four types of electronically collected outcome data: PRO, ClinRO, ObsRO and PerfO. ePRO is the subset reported directly by the patient, without interpretation from a clinician.

Is ePRO a type of eCOA, or a separate system?

ePRO is one of the four data types inside eCOA, not a separate system. A platform that supports eCOA supports ePRO by definition; the reverse isn't true, since an eCOA program can run on clinician-reported or performance-based data alone.

When should a study use ePRO instead of broader eCOA?

When the protocol needs the patient's own account of symptoms, pain, fatigue or quality of life, without a clinician's interpretation between the patient and the data. Studies with multiple assessment sources (investigator, caregiver, patient) call for the broader eCOA framework instead.

Do ePRO and eCOA follow the same regulatory requirements?

Yes, the same rules apply to both. In the US, 21 CFR Part 11 applies to electronic records from trials under an IND or IDE and to records submitted to the FDA (FDA, 2024). In the EU, the EMA guideline on computerised systems (2023) applies the same ICH E6 standards to ePRO data as to other collection methods.

Can a study switch from paper PRO to ePRO mid-study?

Yes, but the change usually needs a protocol amendment, and the electronic version must measure what the paper one measured, since the trial pools both. The FDA (October 2025) considers new comparability evidence unlikely to be necessary for small to moderate changes made under best practices, such as those of the Critical Path Institute's ePRO Consortium.

Florentin Ory
CEO & Co-Founder

Florentin combines clinical research know-how with a true passion for product design. Attentive to detail and obsessed with user experience, he ensures that Datacapt remains a high-performance platform that’s also intuitive and accessible to every user.